reference/19471914

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/19471914

Outgoing Links

Predicate	Object
contentType	Clinical Trial, Phase I\|Clinical Trial, Phase II\|Journal Article\|Multicenter Study\|Research Support, N.I.H., Extramural\|Research Support, Non-U.S. Gov't\|Research Support, U.S. Gov't, Non-P.H.S.
endingPage	1117
issn	1470-2045
issueIdentifier	12
pageRange	1109-1117
publicationName	The Lancet. Oncology
startingPage	1109
hasFundingAgency	http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_b5ad88fdb9d8a30d34a9b7f844c05af4
isSupportedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_cea85b96f9d6d255509e1777a075f57d http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_4a79863896a5d8c9677f07bd150ee8b6 http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_0b0ee35cdb950cab4a7bae1715ae8e55 http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_6382abcc2ad6a608a5124e3b5384d255 http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_ab80a732b5df33e85751c0a758afb577 http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_f278cdc33660d2e2a7b739286215f5a9
bibliographicCitation	Coleman RL, Duska LR, Ramirez PT, Heymach JV, Kamat AA, Modesitt SC, Schmeler KM, Iyer RB, Garcia ME, Miller DL, Jackson EF, Ng CS, Kundra V, Jaffe R, Sood AK. Phase 1–2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer. The Lancet Oncology. 2011 Nov;12(12):1109–17. doi: 10.1016/s1470-2045(11)70244-3.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_51bc331493631f466bc2fabdc726ea63 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f5985a09614205c7ff8620d6f27bc5e6 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b7d9b08904476d1bcf8fbbafe39c5830 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_431717dca5bf41838c48934b13ce1a14 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a6babd4983ba844e2e3357db2a4567e2 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_9359b2b9b27772ecba1abf0f2a0082b6 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_65298eaae6b8c95588c4408b88e041c7 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_969362b70073bc4b527641218b695e66 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_988730eb3e8709d7d6096045bf3929d9 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_2d1cd3ae35286947f2ffe824c67addee http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f5cd03e74fefafbfaa7db63a7df2a51e http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_8213e969148cee07cae0caaae7d9e7ad http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_cba9fafafcbf7cfa1fdd877fe15d125e http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_3331aea30b97f34e45206489d72e8572 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_14bb735aad208b8acdd04bf62e408c4f
date	201111
identifier	https://pubmed.ncbi.nlm.nih.gov/21992853 https://doi.org/10.1016/s1470-2045%2811%2970244-3 https://pubmed.ncbi.nlm.nih.gov/PMC3444811
isPartOf	http://rdf.ncbi.nlm.nih.gov/pubchem/journal/27004 https://portal.issn.org/resource/ISSN/1470-2045
language	English
source	https://www.crossref.org/ https://pubmed.ncbi.nlm.nih.gov/
title	Phase 1–2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer
discusses	http://id.nlm.nih.gov/mesh/M0184558 http://id.nlm.nih.gov/mesh/M0018640 http://id.nlm.nih.gov/mesh/M0443608 http://id.nlm.nih.gov/mesh/M0527034 http://id.nlm.nih.gov/mesh/M0185203
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D000971Q000627 http://id.nlm.nih.gov/mesh/D010051Q000188 http://id.nlm.nih.gov/mesh/D010534Q000188 http://id.nlm.nih.gov/mesh/D005185Q000188
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D011993Q000008 http://id.nlm.nih.gov/mesh/D008297 http://id.nlm.nih.gov/mesh/D000328 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D013997 http://id.nlm.nih.gov/mesh/D000971Q000493 http://id.nlm.nih.gov/mesh/D010051Q000473 http://id.nlm.nih.gov/mesh/D008875 http://id.nlm.nih.gov/mesh/D005260 http://id.nlm.nih.gov/mesh/D040262 http://id.nlm.nih.gov/mesh/D009364 http://id.nlm.nih.gov/mesh/D014481 http://id.nlm.nih.gov/mesh/D000368 http://id.nlm.nih.gov/mesh/D043823Q000008 http://id.nlm.nih.gov/mesh/D000369 http://id.nlm.nih.gov/mesh/D000971Q000009 http://id.nlm.nih.gov/mesh/D010534Q000473 http://id.nlm.nih.gov/mesh/D005185Q000473 http://id.nlm.nih.gov/mesh/D000077143 http://id.nlm.nih.gov/mesh/D016896
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7464 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8102 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9309 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7697 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8607 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11449 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8661 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID23939 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7521 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8752 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID148124 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8321 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8989 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7706

Incoming Links

Predicate	Subject
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129159660

Showing number of triples: 1 to 84 of 84.